Detection of TMPRSS2-ERG in circulating tumor cells in therapy-naive patients and in castration-resistant prostate cancer patients following treatment suggests potential applications in non-invasive monitoring of the therapeutic response [144]. This evidence concerns the gene ERG and prostate cancer.